1、White PaperUncovering Insights:Tapping into APACs Potential for Obesity Clinical Trials A Survey Across Ten Asia Pacific CountriesCECILIA SISON,MD,FPCP,FPSG,Medical Director,Medical Science and Strategy,Asia ENA LYN ANG,MD,FPCP,FPSG,Medical Director,Medical Science and Strategy,Asia CHARU GAUTAM,MBB

2、S,MD,DNB,Senior Medical Director,Medical Science and Strategy,Asia SUJATA ROUTRAY,Clinical Planning Analyst,IQVIA APAC R&DSTable of contentsIntroduction 1Global status of obesity trials 2Objectives 2Methodology 2Results 4Investigator credentials and experience 4Epidemiology 4Patient pathway 5Diagnos

3、is 5Management and treatment 7Clinical trial experience of participating investigators 9Discussion 9Conclusion 15Disclosure 15Acknowledgment 15References 16About the authors 20 |1Obesity has become a global health problem.The global prevalence of obesity,defined as a body mass index(BMI)25kg/m,is pr

4、edicted to rise from 14%to 24%in 2020 and 2035,respectively.It is estimated that almost 2 billion will be affected by 2035.1In the Asia Pacific(APAC)region,obesity has also become a major public health concern with increasing prevalence rates.Australia has a high obesity prevalence of 31.3%based on

5、an Australian National Health Survey in 201718.2 It is similar in New Zealand at 32.5%.3 In India,the prevalence of obesity is approximately 14%using a BMI cut-off for the Asian population(27.5 kg/m2).4 In South Korea,the overall prevalence of obesity(BMI 25 kg/m2)increased from 30.2%in 2012 to 38.4

6、%in 2021,a 1.27-fold increase in 9 years.5 In Pakistan,World Health Organization(WHO)data indicates that 43.9%of the population is obese,and when Asian BMI cutoffs are applied,the prevalence is higher at 58.1%.6Among countries in Southeast Asia,Malaysia has the highest obesity prevalence rate of 33.